ARS Pharmaceuticals, Inc.
SPRY
$14.88
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 4,086.70% | 313.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4,086.70% | 313.60% | |||
| Cost of Revenue | -14.18% | -33.27% | |||
| Gross Profit | 3,451.80% | 60.82% | |||
| SG&A Expenses | 84.08% | 113.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 65.37% | 50.35% | |||
| Operating Income | 317.02% | -41.77% | |||
| Income Before Tax | 362.56% | -52.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 361.05% | -52.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 361.05% | -52.83% | |||
| EBIT | 317.02% | -41.77% | |||
| EBITDA | 317.36% | -41.80% | |||
| EPS Basic | 360.12% | -52.44% | |||
| Normalized Basic EPS | 353.57% | -52.48% | |||
| EPS Diluted | 313.34% | -52.44% | |||
| Normalized Diluted EPS | 307.14% | -52.48% | |||
| Average Basic Shares Outstanding | 0.38% | 0.21% | |||
| Average Diluted Shares Outstanding | 22.86% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||